ArticleInsights into imaging2026
Radiomic signatures associated with longitudinal TNM downstaging for prognostic stratification in breast cancer.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThe tumor-node-metastasis (TNM) staging system is vital for evaluating treatment efficacy in breast cancer patients undergoing neoadjuvant chemotherapy (NACT). However, the prognostic significance of longitudinal TNM changes remains unclear. This study aimed to develop radiomic signatures associated with TNM downstaging (dTNM) and to evaluate their utility in prognostic stratification for breast cancer patients. MATERIALS AND
methodsThe prognostic analysis included a development cohort (n = 292) and two external validation sets (n = 180, n = 61), all with DCE-MRI data and follow-up information. A random forest-based multitask model was developed using radiomic features from DCE-MRI to predict recurrence, pathological complete response (pCR), and dTNM in the development cohort, stratifying patients into distinct groups. The model's discriminative performance was assessed with the area under the curve (AUC). In the external validation set, a multivariable Cox proportional hazards model evaluated the prognostic significance of the groups stratified by the radiomic signatures.
resultsThe multitask model, incorporating 17 imaging features, achieved AUCs of 0.905, 0.795, and 0.818 for predicting recurrence, pCR, and dTNM, respectively, in the inner validation set from the development dataset. External validation showed that, after adjusting for clinicopathological factors, the dTNM-related radiomic signatures were independently associated with better overall survival (OS) and recurrence-free survival (RFS) (p < 0.001 and p = 0.004, respectively). Furthermore, group stratification by radiomic signatures associated with pCR and dTNM demonstrated significant differences in survival (all p < 0.001) in both external validation datasets.
conclusionRadiomic signatures of dTNM can be a prognostic indicator for survival outcomes in breast cancer. CRITICAL RELEVANCE: This study demonstrates that radiomic signatures associated with dTNM offer valuable prognostic insights for survival and recurrence outcomes. KEY POINTS: The imaging-based model can predict longitudinal TNM staging. Radiomic signatures of dTNM demonstrate significant prognostic value. dTNM-associated radiomic signatures provide better prognostic stratification than pCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.